Regarding the therapeutic potential of erasers, Sun et al. discovered that combining Sirt2 inhibitors with copper ion carriers, such as Elesclomol, effectively address the challenges posed by elevated copper and acidity levels in gastric cancer (GC) [48]. The gene discussed is SIRT2; the disease is gastric cancer.